Teriflunomide
Links shared publicly online about this topic
Brass and Ivory: Clinical Research Study: Teriflunomide
brassandivory.blogspot.com — “Support and advice for living and coping with multiple sclerosis and rheumatoid arthritis. Read about one woman\” View full resource at brassandivory.blogspot.com
Most Recently Shared on January 26, 2010 at 6:11 pm By:
Clinical Research Study: Teriflunomide: The following research study is enrolling. For information about the dru.. http://tinyurl.com/d5l3ax
Teriflunomide Successfully Reduces Relapses And Is Well Tolerated In Multiple Sclerosis Patients
medicalnewstoday.com — “Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relaps” View full resource at medicalnewstoday.com
Most Recently Shared on October 16, 2010 at 11:37 am By:
Teriflunomide Successfully Reduces Relapses And Is Well Tolerated In Multiple Sclerosis Patients Sanofi-aventis (EURONE.. http://dld.bz/zMHD
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients - Drugs.com MedNews
drugs.com — “- One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting Sanofi-aventis (EURONEXT SAN and NYSE SNY) reported today new one-year data from a Phase II study” View full resource at drugs.com
Most Recently Shared on June 7, 2010 at 6:50 pm By:
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients: PARIS,... http://bit.ly/c1x7WK
Genzyme Reports Top-line Results For TENERE Study Of Oral Teriflunomide In Relapsing Multiple Sclerosis
medicalnewstoday.com — “Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily” View full resource at medicalnewstoday.com
Most Recently Shared on December 22, 2011 at 9:05 am By:
Genzyme Reports Top-line Results For TENERE Study Of Oral Teriflunomide In Relapsing Multiple Sclerosis http://t.co/yaggSM6T
Sanofi moves teriflunomide into phase III MS trials | InPharm
inpharm.com — “Sanofi moves teriflunomide into phase III MS trials | InPharm” View full resource at inpharm.com
Most Recently Shared on October 26, 2010 at 10:35 am By:
Pharmafocus Health News and Pharma
Sanofi moves teriflunomide into phase III MS trials http://ht.ly/2Zr0I
Multiple sclerosis: Teriflunomide appears safe and effective as part of combination therapy, study suggests
sciencedaily.com — “A Phase II study analyzed the effect of teriflunomide, an investigational oral medication for relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. The study analyzed teriflunomide added to ongoing treatment with glatiramer acetate, a currently prescribed medication, and determined that teriflunomide was safe and effective as part of combination therapy.” View full resource at sciencedaily.com
Most Recently Shared on April 15, 2010 at 1:18 am By:
Multiple sclerosis: Teriflunomide appears safe and effective as part of combination therapy, study suggests http://ow.ly/174vDv
Multiple sclerosis: Teriflunomide appears safe and effective as part of combination therapy, study suggests
sciencedaily.com — “A Phase II study analyzed the effect of teriflunomide, an investigational oral medication for relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. The study analyzed teriflunomide added to ongoing treatment with glatiramer acetate, a currently prescribed medication, and determined that teriflunomide was safe and effective as part of combination therapy.” View full resource at sciencedaily.com
Most Recently Shared on April 14, 2010 at 8:08 pm By:
Multiple sclerosis: Teriflunomide appears safe and effective as part of combination therapy, study suggests: A Pha... http://bit.ly/cZoLM7
Teriflunomide Successfully Reduces Relapses And Is Well Tolerated In Multiple Sclerosis Patients - QualityPoint Technologies
qualitypointtech.net — “Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced b” View full resource at qualitypointtech.net
Most Recently Shared on October 16, 2010 at 4:17 pm By:
Teriflunomide Successfully Reduces Relapses And Is Well Tolerated In Multiple Sclerosis Patients: Sanofi-aventis (... http://bit.ly/awTFDI
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients - Health News - redOrbit
redorbit.com — “PARIS, October 15, 2010 /PRNewswire-FirstCall/ -- - Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).” View full resource at redorbit.com
Most Recently Shared on October 15, 2010 at 1:07 pm By:
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients: PARIS , October ... http://bit.ly/9aUgEf
Teriflunomide Beneficial in Most Patients With Relapsing MS - QualityPoint Technologies
qualitypointtech.net — “A subgroup analysis of MRI data reveals that most types of patients with relapsing forms of multiple sclerosis benefit from the novel agent teriflunomide. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on July 5, 2011 at 9:45 pm By:
Teriflunomide Beneficial in Most Patients With Relapsing MS: A subgroup analysis of MRI data reveals that most typ... http://bit.ly/oI3ooP
Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis
news-medical.net — “Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated wi” View full resource at news-medical.net
Most Recently Shared on June 7, 2010 at 11:20 am By:
Sanofi-aventis reports new 1-year data from teriflunomide Phase II study for relapsing multiple sclerosis: Sanofi-... http://bit.ly/cd3dem
Presseportal: sanofi-aventis Group - Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
presseportal.de — “sanofi-aventis Group: Paris, August 30, 2010 (ots/PRNewswire) - Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate” View full resource at presseportal.de
Most Recently Shared on August 30, 2010 at 5:23 am By:
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients: Paris, August 3... http://bit.ly/cepMtE
PolygenicBlog: Teriflunomide Successfully Reduces Relapses And Is Well Tolerated In Multiple Sclerosis Patients
polygenicpathways.blogspot.com — “Concerning the relationships between genes, risk factors and immunity in Alzheimer's disease, Autism, Bipolar disorder , multiple sclerosis, Parkinson's disease, schizophrenia and chronic fatigue” View full resource at polygenicpathways.blogspot.com
Most Recently Shared on October 17, 2010 at 4:23 pm By:
http://www.linkedin.com/pub/chris-carter/22/560/76a" /> Dr Chris Carter Pharmacist, PhD, Doctor, and Medical Technology
Teriflunomide Successfully Reduces Relapses And Is Well Tolerated In Multiple Sclerosis… http://goo.gl/fb/u1qAI
Results from Trial Comparing Teriflunomide and Rebif in Relapsing MS Do Not Meet Primary Goal : National MS Society
nationalmssociety.org — “MS stops people from moving. The National MS Society exists to make sure it doesn't.” View full resource at nationalmssociety.org
Most Recently Shared on December 20, 2011 at 10:24 pm By:
News! Results from Trial Comparing Teriflunomide and Rebif in Relapsing MS Do Not Meet Primary Goal http://t.co/PZIyCR1e
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate AndDisability Progression
medicalnewstoday.com — “Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The” View full resource at medicalnewstoday.com
Most Recently Shared on October 8, 2011 at 8:05 am By:
MNT Pharma News Health News and Pharma
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate A... http://mnt.to/42bg
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Lisa Emrich
Patient Advocate and Blogger, Living with Multiple Sclerosis and Rheumatoid Arthritis, Musician, Educator, and writer for HealthCentral.com
-
medical_tweets
-
OrganizedWisdom MS
Organizing multiple sclerosis resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
